Table 1.
Baseline patient characteristics
| Characteristic | Aliskiren + ARB Group | ARB Group | P value |
|---|---|---|---|
| |
N = 57 |
N = 132 |
|
| Demographic |
|
|
|
| Age |
63.9 ± 19.3 |
66.5 ± 15.4 |
0.367 |
| Male gender |
61.4% (n = 35) |
68.9% (n = 91) |
0.313 |
| Clinical |
|
|
|
| Body-mass index |
24.8 ± 3.9 |
25.2 ± 3.7 |
0.548 |
| Mean sitting blood pressure-mmHg |
|
|
|
| Systolic |
134.9 ± 16.6 |
131.0 ± 14.0 |
0.123 |
| Diastolic |
77.2 ± 10.8 |
77.4 ± 10.5 |
0.135 |
| Urine protein-to-creatinine ratio |
1.84 (0.89 ∼ 2.77) |
1.81 (0.84 ∼ 2.78) |
0.723 |
| Estimated glomerular filtration rate ml/min/1.73 m2 |
50.9 ± 31.1 |
42.5 ± 19.9 |
0.062 |
| Hemoglobin (g/liter) |
12.0 ± 1.9 |
11.8 ± 1.9 |
0.525 |
| Chronic kidney disease stage |
|
|
0.173 |
| Stage I |
10.5% (n = 6) |
4.5% (n = 6) |
|
| Stage II |
17.5% (n = 10) |
7.6% (n = 10) |
|
| Stage IIIA |
14.0% (n = 8) |
23.5% (n = 31) |
|
| Stage IIIB |
28.1% (n = 16) |
36.4% (n = 48) |
|
| Stage IV |
29.8% (n = 17) |
28.0% (n = 37) |
|
| Etiology |
|
|
0.917 |
| Hypertensive nephropathy |
36.8% (n = 21) |
34.1% (n = 45) |
|
| Chronic glomerulonephritis |
43.9% (n = 25) |
47.0% (n = 62) |
|
| Interstitial nephritis |
19.3% (n = 11) |
18.9% (n = 25) |
|
| Triglycerides (mg/dl) |
146.3 ± 100.2 |
133.0 ± 79.4 |
0.369 |
| Cholesterol (mg/dl) |
|
|
|
| Total |
198.9 ± 52.4 |
183.7 ± 45.7 |
0.062 |
| Low-density lipoprotein |
116.4 ± 38.8 |
112.4 ± 37.7 |
0.567 |
| High-density lipoprotein |
51.8 ± 14.0 |
48.6 ± 17.3 |
0.309 |
| Serum potassium (mmol/liter) |
4.2 ± 0.5 |
4.4 ± 0.6 |
0.037 |
| Antihypertensive drugs received at baseline |
|
|
|
| Calcium-channel blocker |
52.6% (n = 30) |
43.9% (n = 58) |
0.272 |
| Beta-blocker |
21.1% (n = 12) |
15.9% (n = 21) |
0.393 |
| Diuretic |
35.1% (n = 20) |
47.0% (n = 62) |
0.130 |
| Alpha-blocker | 14.0% (n = 8) | 5.3% (n = 7) | 0.042 |